Skip to main content

Table 2 Meta-analysis of the COMT Val158Met polymorphism on BC susceptibility

From: Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis

Comparison

Population

Sample size

No. of studies

Test of association

Mode

Test of heterogeneity

  

Case

Control

 

OR

95% CI

P value

 

χ 2

P value

I 2

LL vs. HH

Overall

17,223

23,069

54

0.999

0.925-1.078

0.976

R

117.76

0.000

55.0

 

Caucasian

12,942

18,066

32

0.960

0.897-1.028

0.240

R

49.28

0.020

37.1

 

Asian

3,009

3,790

17

1.243

0.942-1.641

0.125

R

54.34

0.000

70.6

 

Pre-

2,095

2,523

21

1.049

0.825-1.334

0.697

R

48.22

0.000

58.5

 

Post-

7,215

10,138

26

0.982

0.875-1.102

0.757

R

45.40

0.008

44.9

 

PB

17,223

23,069

28

0.999

0.925-1.078

0.381

R

48.00

0.008

43.7

 

HB

3,800

6,169

20

1.151

0.946-1.402

0.160

R

58.86

0.000

67.7

 

FB

1,351

1,140

5

0.848

0.712-1.010

0.064

F

4.43

0.351

9.7

HL vs. HH

Overall

22,589

33,568

54

1.005

0.959-1.052

0.845

R

72.70

0.038

27.1

 

Caucasian

19,059

25,912

32

0.999

0.958-1.042

0.968

F

30.14

0.510

0.0

 

Asian

4,525

5,781

17

1.052

0.923-1.200

0.448

R

36.85

0.002

56.6

 

Pre-

3,204

3,877

21

0.962

0.871-1.062

0.440

F

27.59

0.119

27.5

 

Post-

10,480

14,476

26

1.009

0.954-1.067

0.762

F

33.83

0.112

26.1

 

PB

17,648

22,679

28

0.987

0.945-1.030

0.547

F

3.60

0.463

0.0

 

HB

5,751

9,128

20

1.075

0.966-1.195

0.187

R

33.89

0.019

43.9

 

FB

2,102

1,674

5

0.950

0.824-1.094

0.476

F

30.98

0.272

12.9

LL vs. HL

Overall

23,594

31,759

54

0.983

0.926-1.045

0.586

R

95.26

0.000

44.4

 

Caucasian

19,579

27,208

32

0.954

0.911-1.001

0.055

F

36.02

0.245

13.9

 

Asian

2,538

3,135

17

1.170

0.895-1.528

0.251

R

49.83

0.000

67.9

 

Pre-

2,507

3,200

21

1.060

0.851-1.320

0.606

R

49.32

0.000

59.4

 

Post-

10,243

14,548

26

0.969

0.915-1.025

0.271

F

32.47

0.271

23.0

 

PB

16,437

21,768

28

0.969

0.909-1.032

0.324

R

39.76

0.054

32.1

 

HB

4,973

8,203

20

1.060

0.902-1.245

0.478

R

48.71

0.000

61.0

 

FB

2,099

1,714

5

0.882

0.769-1.012

0.073

F

4.37

0.358

8.6

LL vs. HL+HH

Overall

34,358

45,429

56

0.988

0.929-1.050

0.702

R

108.88

0.000

51.3

 

Caucasian

25,790

35,593

32

0.956

0.909-1.006

0.081

R

43.54

0.067

28.8

 

Asian

5,770

7,552

17

1.204

0.927-1.564

0.164

R

52.91

0.000

69.8

 

Pre-

3,903

4.800

21

1.053

0.855-1.297

0.627

R

49.44

0.000

59.5

 

Post-

13,969

19,581

26

0.980

0.901-1.065

0.629

R

37.85

0.048

33.9

 

PB

24,205

31,307

30

0.966

0.906-1.030

0.290

R

45.36

0.015

40.5

 

HB

7,262

11,750

20

1.098

0.934-1.289

0.257

R

54.38

0.000

65.1

 

FB

2,776

2,264

5

0.877

0.760-1.013

0.074

F

4.62

0.328

13.5

LL+HL vs. HH

Overall

34,358

45,429

56

1.001

0.954-1.051

0.953

R

93.20

0.001

41.0

 

Caucasian

25,790

35,593

32

0.982

0.944-1.022

0.369

F

37.71

0.189

17.8

 

Asian

5,770

7,552

17

1.072

0.952-1.208

0.253

R

42.65

0.001

60.1

 

Pre-

3,933

4.839

22

1.016

0.890-1.160

0.815

R

33.81

0.038

37.9

 

Post-

14,001

19,604

27

1.001

0.924-1.084

0.987

R

40.17

0.038

35.3

 

PB

24,205

31,307

30

0.975

0.924-1.028

0.343

R

42.89

0.047

32.4

 

HB

7,262

11,750

20

1.091

0.978-1.216

0.118

R

39.26

0.004

51.6

 

FB

2,776

2,264

5

0.914

0.799-1.044

0.186

F

3.81

0.432

0.0

  1. OR odds ratio, CI confidence intervals, R random effects model, F fixed effects model, PB Population-based study, HB Hospital-based study, FB Familial-based study, Pre- Premenopausal, Post- Postmenopausal.